How long does it take for resistance to Brigatinib/Brigatinib to develop?

Brigatinib/Brigatinib (Brigatinib) has shown a long resistance time in the treatment of ALK-positive non-small cell lung cancer (NSCLC) patients. However, each patient's situation is unique, and the time to resistance may vary based on factors such as individual differences, tumor characteristics, and treatment history. The following is some basic information about resistance to brigatinib/brigatinib:

1.Time to initial resistance: For ALKfusion-positiveNSCLC patients who receive first-line treatment, brigatinib/bugatinib usually shows a longer time to initial resistance. According to clinical trial data, the initial resistance time (median time to resistance) of brigatinib/brigatinib is usually more than 12 months.

2.Multiple drug resistance mechanisms: Drug resistance is the process in which tumors gradually lose sensitivity to therapeutic drugs, and may involve multiple drug resistance mechanisms. Forbrigatinib/brigatinib, common resistance mechanisms includeALKsecondary mutations, such asALK, as well as activation of other kinase signaling pathways.

3.Resistance management: When patients develop drug resistance, the treatment plan needs to be re-evaluated. Depending on the resistance mechanism and clinical situation, genetic testing and imaging evaluation may be required to determine the next treatment strategy. For some ALKresistance mutations, such as ALK’s G1202R mutation, other ALKs may be consideredInhibitors or switching to next-generation ALKinhibitors.

It should be noted that drug resistance is the result of tumor evolution and adaptation to treatment pressure, and in some patients, multiple drug resistance events may occur. Therefore, management of treatment resistance is an ongoing process that requires close monitoring of patient efficacy and tolerability and individualized treatment decisions based on the latest research and clinical guidelines.

In summary, Brigatinib/Brigatinib showed a longer initial resistance time in the treatment of ALKpositive NSCLC patients, but the resistance time may be different in each patient. Resistance may involve multiple mechanisms, and the management of treatment resistance requires comprehensive consideration of the patient's condition and individualized treatment decisions based on the latest research and guidelines. Close patient monitoring and collaboration with physicians are important to promptly adjust treatment regimens and address drug resistance.

Brigatinib/Brigatinib has been launched in China and has been included in medical insurance. Since it has just been approved for marketing, patients may not be able to buy it in domestic pharmacies. If you need to purchase it in China, please consult the local pharmacy. However, the price is quite high, more than 10,000 yuan. Foreign Brigatinib/Brigatinib are mainly generic drugs, mainly Bangladeshi and Laos generic drugs. The price of the international version of the Bangladeshi generic drug Yaopin is about 2000yuan, the specification is 90mg*30 tablets; the price of the Laos version of the generic drug is about 600, and the specification is smaller. And the ingredients of domestic original drugs and foreign generic drugs are basically the same.